Neximmune

Neximmune FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Neximmune (NEXI) as of Oct 18, 2026 is 83.91 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 93.88 % — a change of -10.62% (lower).

FCF Conversion

83.91 %

YoY

-10.62%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Neximmune is 2022 83.91 % . FCF Conversion Rate (FCF/EBITDA) of Neximmune was 2021 93.88 % . It decreases by -10.62% lower compared to the previous year.

The Neximmune FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
80.89 USD
Jan 1, 2019
89.06 USD
Jan 1, 2020
82.23 USD
Jan 1, 2021
93.88 USD
Jan 1, 2022
83.91 USD
The Neximmune FCF Conversion history
YEARFCF ConversionYoY
83.91 %-10.62%
93.88 %+14.16%
82.23 %-7.66%
89.06 %+10.10%
80.89 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Neximmune Stock analysis

What does Neximmune do? Neximmune Inc, trading under ticker NEXI, is a US-based biotechnology company headquartered in Gaithersburg. Founded in 2021, the company went public on February 12, 2021. It employs 50 people and operates in the Health Care sector. Neximmune focuses on developing immunotherapies using its Artificial Immune Modulation (AIM) platform, which employs nanoparticles to direct T cell responses. The company's product candidates include NEXI-001 for acute myeloid leukemia and NEXI-002 for multiple myeloma. Its AIM technology constructs synthetic dendritic cells to generate targeted immune responses. The company is clinical-stage, developing treatments for oncology and autoimmune disorders. Neximmune is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Neximmune stock

FCF Conversion Rate (FCF/EBITDA) of Neximmune is 83.91 % in 2022.

FCF Conversion Rate (FCF/EBITDA) of Neximmune changed from 93.88 % to 83.91 %, representing a -10.62% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Neximmune since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Neximmune with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Neximmune

All Key Metrics — Neximmune